<DOC>
	<DOCNO>NCT00401115</DOCNO>
	<brief_summary>The purpose study determine safety tolerability MS-R001 escalating dose patient diabetic macular edema secondary diabetic retinopathy</brief_summary>
	<brief_title>Safety Tolerability MS-R001 Patients With Diabetic Macular Edema Secondary Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria include limited : Diagnosed diabetes mellitus Visual acuity 20/40 20/200 study eye Exclusion Criteria include limited : Any ocular disease could compromise vision study eye Intraocular surgery study eye within 90 day prior study start Capsulotomy study eye within 30 day prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>